C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
Completed
- Conditions
- Hypercholesteremia
- Registration Number
- NCT00688454
- Lead Sponsor
- AstraZeneca
- Brief Summary
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3392
Inclusion Criteria
- Patients with hypercholesteremia who was never treated with statins before
- Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR
Read More
Exclusion Criteria
- None
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin 3 visits within 10 weeks
- Secondary Outcome Measures
Name Time Method Tolerability of CRESTOR-therapy 3 visits within 10 weeks